Clinical status and optimal use of rituximab for B-cell lymphomas.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Oncology

• Publication date

  1998-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 9874849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

  1998cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

  1997cited by this paper
• High-dose therapy and transplantation for low-grade lymphoma.

  1997cited by this paper
• IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

  1997cited by this paper
• IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

  1997cited by this paper
• Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

  1996cited by this paper
• Cladribine in the treatment of low-grade non-Hodgkin's lymphoma.

  1996cited by this paper
• Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.

  1995cited by this paper
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994cited by this paper
• Antibodies as cytotoxic therapy.

  1994cited by this paper
• Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

  1994cited by this paper
• Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.

  1994cited by this paper
• Monoclonal antibody-based therapies of leukemia and lymphoma.

  1992cited by this paper
• Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

  1992cited by this paper
• Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.

  1988cited by this paper
• Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.

  1987cited by this paper
• Long‐term results of treatment of patients with follicular lymphomas

  1987cited by this paper
• High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma.

  1987cited by this paper
• Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.

  1985cited by this paper
• The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

  1985cited by this paper
• The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.

  1985cited by this paper
• Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.

  1984cited by this paper
• Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation.

  1984cited by this paper
• Characterization of a human B lymphocyte-specific antigen.

  1980cited by this paper

• Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence

  2021cites this paper
• Safety of rituximab on testicles, a double-blindedcontrolled trial in mice

  2020cites this paper
• Paper de la via de senyalització del receptor de cèl·lules B (BCR) en la interacció entre les cèl·lules de leucèmia limfàtica crònica i el microambient tumoral

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• The challenge of co-existence : from graft-versus-host disease to stable mixed chimerism after allogeneic hematopoietic stem cell transplantation

  2017cites this paper
• Characterization of the inflammatory infiltrates associated with oral epithelial dysplasia and oral squamous cell carcinoma

  2017cites this paper
• [Treatment of nephrotic syndrome: immuno- or rather podocyte therapy?].

  2016cites this paper
• Current Status of Immunotherapy Treatments for Pancreatic Cancer

  2016cites this paper
• The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

  2015influential citation
• B cells and the Antibody-Dependent Immune Response in Cancer and Infection

  2015cites this paper
• Case studies of monoclonal antibodies for cancer therapy: technology drives clinical development

  2015cites this paper
• The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma

  2015cites this paper
• BCellsRegulateMacrophagePhenotypeandResponse to Chemotherapy in Squamous Carcinomas

  2014cites this paper
• Developing T cell cancer immunotherapy in the dog with lymphoma.

  2014cites this paper
• Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.

  2014cites this paper
• B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.

  2014cites this paper
• IDENTIFICATION OF PANCREATIC CANCER-SPECIFIC ANTIGENS USING A NOVEL QUANTITATIVE SEROPROTEOMICS APPROACH

  2014cites this paper
• B cells and their mediators as targets for therapy in solid tumors.

  2013cites this paper
• A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab

  2013cites this paper
• Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab

  2013cites this paper
• Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.

  2013cites this paper
• Polymer-drug conjugates: origins, progress to date and future directions.

  2013cites this paper
• New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

  2013cites this paper
• Treatment of relapsed or refractory chronic lymphocytic leukemia.

  2012cites this paper
• Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle.

  2012cites this paper
• Radioimmunotherapy

  2012cites this paper
• Rituximab: current status as therapy for malignant and benign hematologic disorders.

  2012cites this paper
• CALCIUM HANDLING IN MYOGENIC PROGENITORS AND SKELETAL MYOBLASTS: THE ROLE OF CD20

  2012cites this paper
• Low‐dose rituximab is effective in pemphigus

  2012cites this paper
• Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy.

  2012cites this paper
• Type 1 Diabetes Immunotherapy - Successes, Failures and Promises

  2011cites this paper
• Immunotherapy-based strategies for the treatment of autoimmune diabetes: searching for the cure.

  2011cites this paper
• The Rituximab in the Study of Relapsed Chronic Lymphocytic Leukemia

  2011cites this paper
• Drug delivery technologies for autoimmune disease

  2010cites this paper
• Rituximab for the treatment of patients with chronic lymphocytic leukemia

  2010cites this paper
• Role of complement in tumour formation : Friend or foe?

  2010cites this paper
• Rituximab-induced pneumonitis on F-18 FDG PET/CT in patient with non-Hodgkin lymphoma.

  2010cites this paper
• Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.

  2010cites this paper
• Targeted therapy for chronic lymphocytic leukemia

  2009cites this paper
• Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.

  2009cites this paper
• Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.

  2009cites this paper
• B cell depletion in Systemic Lupus Erythematosus

  2009cites this paper
• Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

  2009cites this paper
• Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.

  2008cites this paper
• Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.

  2008cites this paper
• Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.

  2008cites this paper
• Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand.

  2008cites this paper
• t(14;18) Translocations and risk of follicular lymphoma.

  2008cites this paper
• In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging

  2008cites this paper
• B Cell Depletion Delays Collagen-Induced Arthritis in Mice : Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity 1

  2007cites this paper
• B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity1

  2007cites this paper
• In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.

  2007cites this paper
• B cell depletion therapy in autoimmune diseases.

  2007cites this paper
• Cancer immunotherapy for the veterinary patient.

  2007cites this paper
• Complement as effector system in cancer immunotherapy.

  2007influential citation
• Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non‐Hodgkin's lymphoma

  2006cites this paper
• Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy

  2006cites this paper
• Ibritumomab tiuxetan for non-Hodgkin’s lymphoma

  2006cites this paper
• Natalizumab and progressive multifocal leucoencephalopathy

  2006cites this paper
• Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

  2006cites this paper
• Development of antibody‐based therapeutics for oncology indications

  2006influential citation
• Immunotherapy in Mice Lymphocytes during Anti-CD20 Niche for B1 and Conventional B The Peritoneal Cavity Provides a Protective

  2005cites this paper
• The absence of CD20 messenger RNA in recurrent cutaneous B‐cell lymphoma following rituximab therapy

  2005cites this paper
• The interplay between innate and adaptive immunity regulates cancer development

  2005cites this paper
• The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice1

  2005cites this paper
• B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides

  2005influential citation
• Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

  2005cites this paper
• The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy

  2004cites this paper
• 1659 The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody

  2004cites this paper
• 131I-rituximab: relationship between immunoreactivity and specific activity.

  2004cites this paper
• Mouse CD20 expression and function.

  2004cites this paper
• Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

  2004cites this paper
• Engineering Antibodies for the Clinic

  2004cites this paper
• Design of a modular immunotoxin connected by polyionic adapter peptides.

  2003cites this paper
• Infections in patients with hematological cancer: recent developments.

  2003cites this paper
• Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

  2003cites this paper
• CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature

  2003cites this paper
• Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1

  2003cites this paper
• The Evolving Role of Monoclonal Antibodies and Dendritic Cell Therapy in Hematologic Malignancies

  2002cites this paper
• Immune-based therapies: A review of clinical endpoints used in trials of selected immunologic agents, by the Forum for Collaborative HIV Research

  2002cites this paper
• Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia

  2002cites this paper
• Production of Immunoglobulins and Monoclonal Antibodies Targeting Infectious Diseases

  2002cites this paper
• Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders

  2002cites this paper
• Cutaneous large B‐cell lymphoma of the leg masquerading 
as a chronic venous ulcer

  2002cites this paper
• Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone

  2001cites this paper
• Guidelines for the use of Rituximab in Non-Hodgkin’s Lymphoma

  2001cites this paper
• Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse.

  2001cites this paper
• Antibodies in the treatment of lymphoma.

  2001cites this paper
• Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome

  2001cites this paper
• CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens

  2001cites this paper
• Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

  2001cites this paper
• Rituximab: perspective on single agent experience, and future directions in combination trials.

  2001cites this paper
• Reply to wadhwa et al

  2000cites this paper
• On The Mechanism Of Inhibition Of Factor Viia By Synthetic Pentasaccharide, Low‐Molecular‐Weight Heparins And Unfractionated Heparin

  2000cites this paper
• Pseudoautosomal linkage in chronic lymphocytic leukaemia

  2000cites this paper
• Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries.

  2000cites this paper
• Life-threatening infections in bone marrow transplant patients

  2000cites this paper
• Traitement du lymphome non Hodgkin à haute teneur et intermédiaire avec anticorps anti-CD20

  2000cites this paper
• Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.

  2000cites this paper
• All‐Trans Retinoic ACID and Low‐Dose Chemotherapy For Acute Promyelocytic Leukaemia

  2000cites this paper